An RCT finds an interdisciplinary care model with family empowerment improves blood pressure, glucose, and psychosocial outcomes in comorbid hypertension and diabetes. PICO summary and commentary.
Browsing: Diabetes
Evidence summaries and landmark trials across type 1, type 2, prevention, glycaemic control, complications, and diabetes technology.
An RCT finds adding ezetimibe to metformin raises PPAR-gamma and adiponectin expression and improves insulin resistance in diabetic fatty liver disease, though endpoints are surrogate. PICO summary and commentary.
An early RCT finds weekly Wharton’s jelly stem cell-derived exosomes markedly accelerate diabetic foot ulcer healing versus standard care, though the therapy remains investigational. PICO summary and commentary.
A phase-1 crossover study in healthy Korean volunteers found a fixed-dose enavogliflozin/gemigliptin combination pharmacokinetically equivalent to the separate tablets, with food delaying only the time to peak. PICO summary and expert commentary.
A multicentre RCT finds adding orlistat to pioglitazone and metformin improves weight, visceral fat, and insulin sensitivity in obese type 2 diabetes, but not HbA1c. PICO summary and commentary.
An RCT finds intraoperative dexmedetomidine reduces glucose variability, insulin requirements, and CRP in diabetic off-pump CABG patients, though endpoints are surrogate. PICO summary and commentary.
A phase 2 RCT finds placenta-derived cell therapy (PDA-002) for diabetic foot ulcers works best at the lowest dose and in the peripheral-artery-disease subgroup, a dose- and subgroup-specific signal. PICO summary and commentary.
A crossover RCT finds weekly structured telehealth modestly lowers HbA1c and improves time in range in poorly controlled paediatric type 1 diabetes, without more hypoglycaemia. PICO summary and commentary.
Summary: In adults with persistent and recalcitrant diabetic foot ulcers that failed to heal with conventional treatment, full-thickness decellularized placental…
A pragmatic cluster RCT finds an SMS lifestyle intervention for prediabetes does not improve HbA1c versus usual care, illustrating that engagement does not equal efficacy. PICO summary and commentary.